Cargando…

Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models

BACKGROUND: Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang, Du, Lei, Li, Qinying, Li, Fang, Wang, Bei, Zhao, Yuanqi, Meng, Qiang, Li, Wenyu, Pan, Juyuan, Xia, Junhui, Wu, Shitao, Yang, Jie, Li, Heng, Ma, Jianhua, ZhangBao, Jingzi, Huang, Wenjuan, Chang, Xuechun, Tan, Hongmei, Yu, Jian, Zhou, Lei, Lu, Chuanzhen, Wang, Min, Dong, Qiang, Lu, Jiahong, Zhao, Chongbo, Quan, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012141/
https://www.ncbi.nlm.nih.gov/pubmed/35432315
http://dx.doi.org/10.3389/fimmu.2022.873576
_version_ 1784687739098103808
author Wang, Liang
Du, Lei
Li, Qinying
Li, Fang
Wang, Bei
Zhao, Yuanqi
Meng, Qiang
Li, Wenyu
Pan, Juyuan
Xia, Junhui
Wu, Shitao
Yang, Jie
Li, Heng
Ma, Jianhua
ZhangBao, Jingzi
Huang, Wenjuan
Chang, Xuechun
Tan, Hongmei
Yu, Jian
Zhou, Lei
Lu, Chuanzhen
Wang, Min
Dong, Qiang
Lu, Jiahong
Zhao, Chongbo
Quan, Chao
author_facet Wang, Liang
Du, Lei
Li, Qinying
Li, Fang
Wang, Bei
Zhao, Yuanqi
Meng, Qiang
Li, Wenyu
Pan, Juyuan
Xia, Junhui
Wu, Shitao
Yang, Jie
Li, Heng
Ma, Jianhua
ZhangBao, Jingzi
Huang, Wenjuan
Chang, Xuechun
Tan, Hongmei
Yu, Jian
Zhou, Lei
Lu, Chuanzhen
Wang, Min
Dong, Qiang
Lu, Jiahong
Zhao, Chongbo
Quan, Chao
author_sort Wang, Liang
collection PubMed
description BACKGROUND: Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP4-ab-positive NMOSD, develop outcome prediction models, and validate them in a multicenter validation cohort. METHODS: Between January 2015 and December 2020, 820 patients with NMOSD were registered at Huashan Hospital. We retrospectively reviewed their medical records, and included 358 AQP4-ab-positive patients with 1135 treatment episodes. Univariate and multivariate analyses were used to explore the predictors of relapse, severe visual or motor disability during follow-up. A model predicting the 1- and 2-year relapse-free probability was developed and validated in an external validation cohort of 92 patients with 213 treatment episodes. RESULTS: Lower serum AQP4-ab titer (< 1:100), higher Expanded Disability Status Scale (EDSS) score at onset (≥ 2.5), and use of intravenous methylprednisolone (IVMP) at the first attack predicted an overall lower annualized relapse rate. Older age (> 48 years), optic neuritis at onset, and higher onset EDSS score (≥ 2.5) significantly increased the risk for blindness, while IVMP at the first attack and maintenance therapy reduced the risk for blindness. Myelitis at onset increased the possibility of motor disability (EDSS ≥ 6.0), severe motor disability or death (EDSS ≥ 8.0), while maintenance therapy reduced these possibilities. Anderson and Gill model identified that the risk factors predicting recurrent relapses under certain treatment status were female gender, high AQP4-ab titer (≥ 1:100), previous attack under same therapy, lower EDSS score at treatment initiation (< 2.5), and no maintenance therapy or oral prednisone lasting less than 6 months. A nomogram using the above factors showed good discrimination and calibration abilities. The concordance indexes in the primary and validation cohort were 0.66 and 0.65, respectively. CONCLUSION: This study reports the demographic, clinical and therapeutic predictors of relapse, and severe visual or motor disability in NMOSD. Early identification of patients at risk of unfavorable outcomes is of paramount importance to inform treatment decisions.
format Online
Article
Text
id pubmed-9012141
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90121412022-04-16 Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models Wang, Liang Du, Lei Li, Qinying Li, Fang Wang, Bei Zhao, Yuanqi Meng, Qiang Li, Wenyu Pan, Juyuan Xia, Junhui Wu, Shitao Yang, Jie Li, Heng Ma, Jianhua ZhangBao, Jingzi Huang, Wenjuan Chang, Xuechun Tan, Hongmei Yu, Jian Zhou, Lei Lu, Chuanzhen Wang, Min Dong, Qiang Lu, Jiahong Zhao, Chongbo Quan, Chao Front Immunol Immunology BACKGROUND: Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP4-ab-positive NMOSD, develop outcome prediction models, and validate them in a multicenter validation cohort. METHODS: Between January 2015 and December 2020, 820 patients with NMOSD were registered at Huashan Hospital. We retrospectively reviewed their medical records, and included 358 AQP4-ab-positive patients with 1135 treatment episodes. Univariate and multivariate analyses were used to explore the predictors of relapse, severe visual or motor disability during follow-up. A model predicting the 1- and 2-year relapse-free probability was developed and validated in an external validation cohort of 92 patients with 213 treatment episodes. RESULTS: Lower serum AQP4-ab titer (< 1:100), higher Expanded Disability Status Scale (EDSS) score at onset (≥ 2.5), and use of intravenous methylprednisolone (IVMP) at the first attack predicted an overall lower annualized relapse rate. Older age (> 48 years), optic neuritis at onset, and higher onset EDSS score (≥ 2.5) significantly increased the risk for blindness, while IVMP at the first attack and maintenance therapy reduced the risk for blindness. Myelitis at onset increased the possibility of motor disability (EDSS ≥ 6.0), severe motor disability or death (EDSS ≥ 8.0), while maintenance therapy reduced these possibilities. Anderson and Gill model identified that the risk factors predicting recurrent relapses under certain treatment status were female gender, high AQP4-ab titer (≥ 1:100), previous attack under same therapy, lower EDSS score at treatment initiation (< 2.5), and no maintenance therapy or oral prednisone lasting less than 6 months. A nomogram using the above factors showed good discrimination and calibration abilities. The concordance indexes in the primary and validation cohort were 0.66 and 0.65, respectively. CONCLUSION: This study reports the demographic, clinical and therapeutic predictors of relapse, and severe visual or motor disability in NMOSD. Early identification of patients at risk of unfavorable outcomes is of paramount importance to inform treatment decisions. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9012141/ /pubmed/35432315 http://dx.doi.org/10.3389/fimmu.2022.873576 Text en Copyright © 2022 Wang, Du, Li, Li, Wang, Zhao, Meng, Li, Pan, Xia, Wu, Yang, Li, Ma, ZhangBao, Huang, Chang, Tan, Yu, Zhou, Lu, Wang, Dong, Lu, Zhao and Quan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Liang
Du, Lei
Li, Qinying
Li, Fang
Wang, Bei
Zhao, Yuanqi
Meng, Qiang
Li, Wenyu
Pan, Juyuan
Xia, Junhui
Wu, Shitao
Yang, Jie
Li, Heng
Ma, Jianhua
ZhangBao, Jingzi
Huang, Wenjuan
Chang, Xuechun
Tan, Hongmei
Yu, Jian
Zhou, Lei
Lu, Chuanzhen
Wang, Min
Dong, Qiang
Lu, Jiahong
Zhao, Chongbo
Quan, Chao
Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
title Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
title_full Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
title_fullStr Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
title_full_unstemmed Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
title_short Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
title_sort neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012141/
https://www.ncbi.nlm.nih.gov/pubmed/35432315
http://dx.doi.org/10.3389/fimmu.2022.873576
work_keys_str_mv AT wangliang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT dulei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT liqinying neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT lifang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT wangbei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT zhaoyuanqi neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT mengqiang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT liwenyu neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT panjuyuan neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT xiajunhui neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT wushitao neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT yangjie neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT liheng neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT majianhua neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT zhangbaojingzi neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT huangwenjuan neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT changxuechun neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT tanhongmei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT yujian neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT zhoulei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT luchuanzhen neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT wangmin neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT dongqiang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT lujiahong neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT zhaochongbo neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels
AT quanchao neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels